Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875896 | 1.00 | BRD4 (0.37) | BRD4BRD2GRM5MAPK1HTR5A | |
| SCHEMBL13283514 | 0.94 | BRD4 (0.38) | BRD4BRD2GRM5MAPK1PIK3CD | |
| SCHEMBL18651543 | 0.94 | BRD4 (0.38) | BRD4BRD2GRM5MAPK1PIK3CD | |
| SCHEMBL13341984 | 0.94 | BRD4 (0.38) | BRD4BRD2GRM5MAPK1PIK3CD | |
| SCHEMBL9251987 | 0.85 | MAPK1 (0.37) | BRD4BRD2MAPK1PIK3CDPER2 | |
| SCHEMBL18883353 | 0.85 | MAPK1 (0.37) | BRD4BRD2MAPK1PIK3CDPER2 | |
| SCHEMBL18821187 | 0.85 | MAPK1 (0.37) | BRD4BRD2MAPK1PIK3CDPER2 | |
| SCHEMBL18666722 | 0.79 | PER2 (0.44) | PIK3CDPER2CRY2 | |
| SCHEMBL25699733 | 0.78 | PER2 (0.39) | PIK3CDPER2CRY2 | |
| SCHEMBL28924468 | 0.78 | ENO1 (0.43) | PER2CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | BRD4 513/4885BRD2 903/4885GRM5 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.